Related Experiment Video
Updated: Aug 11, 2026
08:25
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
Published on: September 9, 2020
[Cancer Early Detection by cfDNA Analyses]
1Dept. of Medical Oncology, JR Sendai Hospital.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 4, 2026
Summary
Analyzing cell-free DNA (cfDNA) shows promise for early cancer detection and monitoring. While multi-cancer early detection (MCED) tests are advancing, further research is needed to improve reliability and clinical efficacy.
Area of Science:
- Oncology
- Genomics
- Biotechnology
Background:
- Cell-free DNA (cfDNA) analysis, particularly circulating tumor DNA (ctDNA), offers a non-invasive approach for cancer detection and monitoring.
- Technological advancements in next-generation sequencing (NGS) enable the detection of low-level ctDNA in blood.
Purpose of the Study:
- To review the current state and technological advancements in cfDNA analysis for early cancer diagnosis.
- To discuss the potential and challenges of multi-cancer early detection (MCED) methods.
Main Methods:
- Analysis of cfDNA fragment characteristics, ctDNA somatic variants, and DNA methylation status.
- Integration of machine learning for enhanced detection accuracy.
Main Results:
- MCED tests are emerging, analyzing cfDNA for early cancer identification and typing.
- Current MCED tests face challenges in sensitivity, specificity, and clinical validation, often complementing existing screening methods.
Conclusions:
- cfDNA analysis, including MCED, holds significant potential for personalized cancer prevention.
- Further research is essential to overcome limitations like improving sensitivity for early-stage cancers and reducing false positives.
